Min-Gu Kim, MD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Gyong Hwa Hong, BS
,
Asan Institute for Life Sciences, Seoul, South Korea
Kyoung Young Lee, BS
,
Asan Institute for Life Sciences, Seoul, South Korea
Eun Hee Ha, BS
,
Asan Institute for Life Sciences, Seoul, South Korea
Keun Ai Moon, MS
,
Asan Institute for Life Sciences, Seoul, South Korea
Sunjoo Park, PhD
,
Asan Institute for Life Sciences, Seoul, South Korea
Hyouk-Soo Kwon, MD, PhD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Tae-Bum Kim, MD, PhD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Hee-Bom Moon, MD, PhD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
You Sook Cho, MD, PhD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Jung-Hyun Kim, MD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Hyo-Jung Kim, MD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
So-Young Park, MD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Bomi Seo, MD
,
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background: Neutrophils play an important role in the development of persistent airflow limitation in asthma, particularly in patients who show poor response to corticosteroids. Human mesenchymal stem cells (hMSCs) has emerged as a new treatment option due to its immunomodulatory effect, however, the role of hMSCs in neutrophilic asthma is not yet understood.
Method: BALB/c mice were exposed to ovalbumin and poly IC to induce neutrophilic airway inflammation. hMSC was administered intravenously, and then, bronchoalveolarlavage (BAL) was done to evaluate differential cell count and measure inflammatory cytokine including IL-8, IL-5, IL-10, IFN-gamma. We also measure cytokines include IL-17, IL-4, IL-10, IFN-gamma released from lymphocyte in pulmonary lymph node. In addition, lung histopathology was done to show peribronchial and perivascular inflammation.
Result: hMSC treatment decreased BAL total cell count (P < 0.001), neutrophils (P < 0.001) and lymphocyte (P < 0.01) IL-5 in BAL fluid was decreased in hMSC treatment group (P < 0.01), however, IL-8, IL-10 and IFN-gamma showed no differences compared with wild type. IL-17 released from lymphocyte in pulmonary lymph node was significantly decreased (P < 0.05). Histopathologic examination revealed that peribronchial inflammation was dramatically decreased in hMSC treatment group..
Conclusion: hMSCs inhibited airway inflammation in poly IC induced neutrophilic asthma model. The mechanism underlying its immunomodulatory effect might be associated with down regulation of IL-17 which has key role in Th17 mediated inflammation.
